Short answer
MEDIFAST INC (MED) filed its Q3 2026 10-Q quarterly report on Oct 26, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $72M (down 19.4% year over year) with net income of −$18M.
Q3 2026 key financials · XBRL
- Revenue
- $72M
- −19.4% YoY · −5.7% QoQ
- Net income
- −$18M
- −674.5% YoY · −464.9% QoQ
- Operating margin
- -26.9%
- Gross margin
- 69.5%
- EPS (diluted)
- −$1.58
- −690.0% YoY · −464.3% QoQ
Source: XBRL data from the MEDIFAST INC (MED) Q3 2026 10-Q on SEC EDGAR. USD.
MEDIFAST INC Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $72.0M, down 19.4% YoY from $89.4M, driven by active earning coaches declining to 10,200 from 19,500
- Gross margin 69.5% vs 69.5% YoY; operating margin (26.9%) vs (4.6%), with net loss $17.5M vs $2.3M
- Average revenue per active earning coach $7,064, up 54.1% from $4,585, the strongest reported performance metric
- Cash, cash equivalents and investments $172.5M vs $167.3M at December 31, 2025; operating cash flow $5.3M vs $12.1M
- Active earning coaches expected to decline through year-end 2026; GLP-1 adoption, inflation and tariffs remain headwinds
Risk Factors
- No material changes to 2025 Form 10-K risk factors disclosed
- Carried-forward risks include regulatory, operational, competitive, market, and financial exposures disclosed in the 2025 Form 10-K
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other MEDIFAST INC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.